AbbVie, Inc. ABBV

NYSEHealth TechnologyUnited States

$295.03+0.58 (+0.20%)

Market closed· Nov 13, 2026, 9:00 PM UTC· USD · Data may be delayed

Day's range: 293.56297.25
52-week range: 190.75302.93

Financial health

– / 5

Analyst view · 30 firms

Buy23 buy · 6 hold · 1 sell

Avg. target $314.81 (+6.7%)

Prices may be delayed and are for informational purposes only - not investment advice.

AbbVie, Inc. ABBV

NYSEHealth TechnologyUnited States

$295.03+0.58 (+0.20%)

Market closed· Nov 13, 2026, 9:00 PM UTC· USD · Data may be delayed

Day's range: 293.56297.25
52-week range: 190.75302.93

Financial health

– / 5

Analyst view · 30 firms

Buy23 buy · 6 hold · 1 sell

Avg. target $314.81 (+6.7%)

Valuation from filings

Calculated from the tables below and the current price ($295.03) · LTM · 2026/9 · 2026-09-30

P/E: 50.78EPS $5.81
P/B: —BV/share $-2.59
P/S: 7.92Sales/share $37.25
Return on equity: —Net income / equity
Net margin: 15.7%Operating margin 32.2%
Free cash flow yield: 3.6%Free cash flow / market cap

Revenue and net income

Fiscal year · $ billions · net margin below

RevenueNet Income

Financial statements

$ millions · Under each value: change against a year earlier

Upgrade to MakklerPRO to see every row.Upgrade to MakklerPRO

Fiscal year	2021	2022	2023	2024	2025	LTM
Income Statement
Revenue	56,197	58,054+3%	54,318-6%	56,334+4%	61,160+9%	66,014
Cost of Revenue
Gross Profit
Operating expenses
Operating Income
Pre-tax income
Income tax (expense) / benefit
Net Income	11,542	11,836+3%	4,863-59%	4,278-12%	4,226-1%	10,342
Earnings per share ($)
Margins
Gross margin
Operating margin
Net margin

Taken from the company's own 10-K and 10-Q filings via the SEC's XBRL data service. The "LTM" column is the last completed fiscal year plus the current year to date, minus the same period a year earlier. Lines a company tags with a non-standard label are left blank rather than filled with an approximation. Not investment advice.